Page 10«..9101112..2030..»

Magenta Therapeutics and Beam Therapeutics Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate (ADC) MGTA-117 as Conditioning Regimen…

By daniellenierenberg

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (Nasdaq: MGTA) and Beam Therapeutics (Nasdaq: BEAM) today announced a non-exclusive research and clinical collaboration agreement to evaluate the potential utility of MGTA-117, Magentas novel targeted ADC for conditioning of patients with sickle cell disease and beta-thalassemia receiving Beams base editing therapies. Beam is pursuing two differentiated base editing approaches to treat hemoglobinopathies: its hereditary persistence of fetal hemoglobin (HPFH) program to precisely and robustly elevate fetal hemoglobin, which could be used in treatments for both sickle cell disease and beta-thalassemia, as well as a novel approach to directly correct the sickle causing point mutation (Makassar).

Conditioning is a critical component necessary to prepare a patients body to receive the edited cells, which carry the corrected gene and must engraft in the patients bone marrow in order to be effective. Todays conditioning regimens rely on nonspecific chemotherapy or radiation, which are associated with significant toxicities. MGTA-117 precisely targets only hematopoietic stem and progenitor cells, sparing immune cells, and has shown high selectivity, potent efficacy, wide safety margins and broad tolerability in non-human primate models. MGTA-117 may be capable of clearing space in bone marrow to support long-term engraftment and rapid recovery in patients.

Beam has demonstrated the ability to edit individual DNA bases in hematopoietic stem cells at high efficiency and with little impact on the viability of edited cells relative to unedited cells using its novel base editing technology. Combining MGTA-117 with Beams HPFH and Makassar base editors could meaningfully advance the treatment of patients with sickle cell disease or beta-thalassemia.

We believe patients will benefit from a more precise process to remove hematopoietic stem cells and prepare them to receive genetic medicines. Magenta has developed targeted ADCs as the preferred modality for our conditioning programs, and we have designed MGTA-117 specifically to optimize it for use with a genetically-modified cell product delivered in a transplant setting, said Jason Gardner, D.Phil., president and chief executive officer, Magenta Therapeutics. Beams next-generation base editing technology complements our next-generation conditioning approach very well, and we are excited to combine these strengths to address the still-significant unmet medical needs of the sickle cell and beta-thalassemia patient communities.

Base editing has the potential to offer lifelong treatment for patients with many diseases, including sickle cell disease and beta-thalassemia. Our novel base editors create precise single base changes in genes without cutting the DNA, enabling durable correction of hematopoietic stem cells with minimal effects on cell viability or genomic integrity, said John Evans, chief executive officer of Beam. Combining the precision of our base editing technology with the more targeted conditioning regimen enabled by MGTA-117 could further improve therapeutic outcomes for patients suffering from these severe diseases. We look forward to partnering with the Magenta team to explore these novel technologies together.

Beam will be responsible for clinical trial costs related to development of Beams base editors when combined with MGTA-117, while Magenta will continue to be responsible for all other development costs of MGTA-117. Magenta will also continue to develop MGTA-117 in other diseases, including blood cancers and genetic diseases. Each company will retain all commercial rights to their respective technologies.

About MGTA-117

MGTA-117, Magentas most advanced conditioning program, is a CD117-targeted antibody engineered for the transplant setting and conjugated to amanitin, a toxin in-licensed from Heidelberg Pharma. It is designed to precisely deplete only hematopoietic stem and progenitor cells and has shown high selectivity, potent efficacy, wide safety margins and broad tolerability in non-human primate models, suggesting that it may be capable of clearing space in bone marrow to support long-term engraftment and rapid recovery in patients. Magenta plans to complete IND-enabling studies this year and initiate clinical studies in 2021. Magenta will continue to develop MGTA-117 in other diseases, including blood cancers and genetic diseases.

About Magenta Therapeutics

Magenta Therapeutics is a clinical-stage biotechnology company developing medicines to bring the curative power of immune system reset through stem cell transplant to more patients with autoimmune diseases, genetic diseases and blood cancers. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant world to revolutionize immune reset for more patients. Magenta is based in Cambridge, Mass. For more information, please visit http://www.magentatx.com. Follow Magenta on Twitter: @magentatx.

About Base Editing and Beam TherapeuticsBeam Therapeutics (Nasdaq: BEAM) is a biotechnology company developing precision genetic medicines through the use of base editing. Beams proprietary base editors create precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This enables a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization focused on its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases. For more information, visit http://www.Beamtx.com.

Magenta Therapeutics Forward-Looking StatementsThis press release may contain forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws, including, without limitation, statements regarding the research and clinical collaboration agreement between Magenta and Beam, including the timing, progress and success of the collaboration contemplated under the agreement, the successful evaluation of MGTA-117 in conjunction with Beams base-editing therapies under the agreement, the anticipated cost allocation and other commercial terms under the agreement, Magentas strategy and business plan, the future development, manufacture and commercialization between Beam and Magenta as well as statements regarding expectations and plans for the anticipated timing of Magentas clinical trials and regulatory filings and the development of Magentas product candidates and advancement of Magentas preclinical programs. The use of words such as may, will, could, should, expects, intends, plans, anticipates, believes, estimates, predicts, projects, seeks, endeavor, potential, continue or the negative of such words or other similar expressions can be used to identify forward-looking statements. The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation, risks set forth under the caption Risk Factors in Magentas most recent Annual Report on Form 10-K filed on March 3, 2020, as updated by Magentas most recent Quarterly Report on Form 10-Q and its other filings with the Securities and Exchange Commission, risks, uncertainties and assumptions regarding the impact of the COVID-19 pandemic to Magentas business, operations, strategy, goals and anticipated timelines, and risks, uncertainties and assumptions inherent in preclinical and clinical studies, including, without limitation, whether results from preclinical studies or earlier clinical studies will be predictive of the results of future trials and the expected timing of submissions for regulatory approval or review by governmental authorities. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although Magenta believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither Magenta nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Beam Forward-Looking Statements

This press release contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about the timing, progress and success of the collaboration contemplated under the agreement between Beam and Magenta, the successful evaluation of MGTA-117 in conjunction with Beams base-editing therapies under the agreement, the expected timing of filing INDs applications and the therapeutic applications of Beams technology. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include the risks and uncertainties, among other things, regarding: the success in development and potential commercialization of our product candidates; Beams ability to obtain, maintain and enforce patent and other intellectual property protection for our product candidates; whether preclinical testing of our product candidates and preliminary or interim data from preclinical and clinical trials will be predictive of the results or success of ongoing or later clinical trials; that enrollment of clinical trials may take longer than expected; that Beams product candidates will experience manufacturing or supply interruptions or failures; that Beam will be unable to successfully initiate or complete the preclinical and clinical development and eventual commercialization of product candidates; that the development and commercialization of Beams product candidates will take longer or cost more than planned; the impact of COVID-19 on Beams business and the other risks and uncertainties identified under the heading Risk Factors and in Beams Annual Reports on Form 10-K for the year ended December 31, 2019 and in Beams Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, and in any subsequent filings with the Securities and Exchange Commission. These forward-looking statements (except as otherwise noted) speak only as of the date of this press release. Factors or events that could cause Beams actual results to differ may emerge from time to time, and it is not possible for Beam to predict all of them. Beam undertakes no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.

Read the original:
Magenta Therapeutics and Beam Therapeutics Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate (ADC) MGTA-117 as Conditioning Regimen...

To Read More: Magenta Therapeutics and Beam Therapeutics Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate (ADC) MGTA-117 as Conditioning Regimen…
categoriaBone Marrow Stem Cells commentoComments Off on Magenta Therapeutics and Beam Therapeutics Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate (ADC) MGTA-117 as Conditioning Regimen… | dataJune 21st, 2020
Read All

For babies born with a rare immune deficiency, a unique new test to better target care – Yahoo India News

By daniellenierenberg

Montreal [Canada], June 18 (ANI): A new test developed at CHU Sainte-Justine in Montreal will enable better management of patients with severe combined immunodeficiency (SCID).

The results of the study were presented in the medical journal Blood Advances published by the American Society of Hematology.

Routine neonatal screening, although not yet available in Quebec, has led to an increase in the incidence of patients diagnosed with SCID in North America in recent years.

This syndrome, a group of rare hereditary genetic disorders, is characterized by a total absence of immune system function, including an absence of T-lymphocytes, the white blood cells that play a crucial role in the body's immune defence.

Without appropriate treatment, the disorder is fatal during the first months of life in the majority of cases.

Many of the genes involved in SCID have been identified, but clinicians sometimes come across patients who do not have any identified genetic abnormalities.

"It's very frustrating. In about seven per cent of patients, we can't provide optimal care because we don't know the genetic cause," said Dr. Elie Haddad, a pediatric immunologist at CHU Sainte-Justine and expert in the field of SCID.

"Depending on the nature of the mutated gene, there are two treatments for SCID: either a bone marrow transplantation or a thymus transplantation. We still need to be able to identify the type of disease in order to choose the correct treatment option," added Haddad.

The gene involved can either disrupt hematopoietic stem cells in the bone marrow that consequently cannot naturally become T-cells, or it can affect the function of the thymus. The thymus is an organ in which immature white blood cells from the bone marrow 'learn' to become T-cells.

When doctors are unable to identify the real cause of the disorder, they usually turn to bone marrow transplantation. They do so for two reasons: first, transplants are easier to perform, and second, among the known genes, more are responsible for a dysfunction of the hematopoietic cells than for a malfunction of the thymus.

However, knowing the origin of the disease is critical, because if it's the thymus that's not working properly, then the bone marrow transplant will have no effect, and vice versa.

"Given this clinical need, our goal was to create a functional test by taking a very small volume of peripheral blood rather than a bone marrow sample, which is a more complex process to perform in babies and more invasive than a simple blood test," said Panojot Bifsha, first author of the study.

In the laboratory, a very small number of stem cells is isolated from patients using a limited amount of blood (3 to 5 mL). A test with a 3D culture that mimics the function of a human thymus is used to test this small number of cells, and a response is obtained in less than five weeks. If the results are normal, thymus transplantation is recommended, but if they are abnormal, then a bone marrow transplant is preferred.

"Our 3D culture system is unique because it allows us to test a very small number of stem cells circulating in the blood and get a relatively quick response. We received blood samples from all over North America, which allowed us to validate our method.

A similar study conducted with bone marrow samples at the U.S. National Institutes of Health (NIH) produced similar results, proving the reliability of the test developed at CHU Sainte-Justine from a blood sample. The U.S. study was also published today in Blood Advances.

As Quebec's hub of care and research for children with rare or serious diseases, CHU Sainte-Justine strives to stay one step ahead in research niches for which it is famous, such as the genetics of rare diseases and innovative treatments in precision medicine.

Additional studies will be required to further validate the latest test and allow it to be used on more patients.(ANI)

Read the original post:
For babies born with a rare immune deficiency, a unique new test to better target care - Yahoo India News

To Read More: For babies born with a rare immune deficiency, a unique new test to better target care – Yahoo India News
categoriaBone Marrow Stem Cells commentoComments Off on For babies born with a rare immune deficiency, a unique new test to better target care – Yahoo India News | dataJune 20th, 2020
Read All

Rheumatoid Arthritis Stem Cell Therapy Market Future Innovation Strategies, Growth & Profit Analysis, Forecast by 2028 – The Cloud Tribune

By daniellenierenberg

The global Rheumatoid Arthritis Stem Cell Therapy market study presents an all in all compilation of the historical, current and future outlook of the market as well as the factors responsible for such a growth. With SWOT analysis, the business study highlights the strengths, weaknesses, opportunities and threats of each Rheumatoid Arthritis Stem Cell Therapy market player in a comprehensive way. Further, the Rheumatoid Arthritis Stem Cell Therapy market report emphasizes the adoption pattern of the Rheumatoid Arthritis Stem Cell Therapy across various industries.Request Sample Reporthttps://www.factmr.com/connectus/sample?flag=S&rep_id=1001The Rheumatoid Arthritis Stem Cell Therapy market report highlights the following players:The global market for rheumatoid arthritis stem cell therapy is highly fragmented. Examples of some of the key players operating in the global rheumatoid arthritis stem cell therapy market include Mesoblast Ltd., Roslin Cells, Regeneus Ltd, ReNeuron Group plc, International Stem Cell Corporation, TiGenix and others.

The Rheumatoid Arthritis Stem Cell Therapy market report examines the operating pattern of each player new product launches, partnerships, and acquisitions has been examined in detail.Important regions covered in the Rheumatoid Arthritis Stem Cell Therapy market report include:

North America (U.S., Canada)Latin America (Mexico, Brazil)Western Europe (Germany, Italy, U.K., Spain, France, Nordic countries, BENELUX)Eastern Europe (Russia, Poland, Rest Of Eastern Europe)Asia Pacific Excluding Japan (China, India, Australia & New Zealand)JapanMiddle East and Africa (GCC, S. Africa, Rest Of MEA)

The Rheumatoid Arthritis Stem Cell Therapy market report takes into consideration the following segments by treatment type:

Allogeneic Mesenchymal stem cellsBone marrow TransplantAdipose Tissue Stem Cells

The Rheumatoid Arthritis Stem Cell Therapy market report contain the following distribution channel:

HospitalsAmbulatory Surgical CentersSpecialty ClinicsHave Any Query? Ask our Industry Experts-https://www.factmr.com/connectus/sample?flag=AE&rep_id=1001

Buy the report at a discounted rate!!! Exclusive offer!!!

The Rheumatoid Arthritis Stem Cell Therapy market report offers a plethora of insights which include:

Changing consumption pattern among individuals globally.Historical and future progress of the global Rheumatoid Arthritis Stem Cell Therapy market.Region-wise and country-wise segmentation of the Rheumatoid Arthritis Stem Cell Therapy market to understand the revenue, and growth lookout in these areas.Accurate Year-on-Year growth of the global Rheumatoid Arthritis Stem Cell Therapy market.Important trends, including proprietary technologies, ecological conservation, and globalization affecting the global Rheumatoid Arthritis Stem Cell Therapy market.

The Rheumatoid Arthritis Stem Cell Therapy market report answers important questions which include:

Which regulatory authorities have granted approval to the application of Rheumatoid Arthritis Stem Cell Therapy in Health industry?How will the global Rheumatoid Arthritis Stem Cell Therapy market grow over the forecast period?Which end use industry is set to become the leading consumer of Rheumatoid Arthritis Stem Cell Therapy by 2028?What manufacturing techniques are involved in the production of the Rheumatoid Arthritis Stem Cell Therapy?Which regions are the Rheumatoid Arthritis Stem Cell Therapy market players targeting to channelize their production portfolio?Get Full Access of the Report @https://www.factmr.com/report/1001/rheumatoid-arthritis-stem-cell-therapy-market

Pertinent aspects this study on the Rheumatoid Arthritis Stem Cell Therapy market tries to answer exhaustively are:

What is the forecast size (revenue/volumes) of the most lucrative regional market? What is the share of the dominant product/technology segment in the Rheumatoid Arthritis Stem Cell Therapy market? What regions are likely to witness sizable investments in research and development funding? What are Covid 19 implication on Rheumatoid Arthritis Stem Cell Therapy market and learn how businesses can respond, manage and mitigate the risks? Which countries will be the next destination for industry leaders in order to tap new revenue streams? Which new regulations might cause disruption in industry sentiments in near future? Which is the share of the dominant end user? Which region is expected to rise at the most dominant growth rate? Which technologies will have massive impact of new avenues in the Rheumatoid Arthritis Stem Cell Therapy market? Which key end-use industry trends are expected to shape the growth prospects of the Rheumatoid Arthritis Stem Cell Therapy market? What factors will promote new entrants in the Rheumatoid Arthritis Stem Cell Therapy market? What is the degree of fragmentation in the Rheumatoid Arthritis Stem Cell Therapy market, and will it increase in coming years?Why Choose Fact.MR?

Fact.MR follows a multi- disciplinary approach to extract information about various industries. Our analysts perform thorough primary and secondary research to gather data associated with the market. With modern industrial and digitalization tools, we provide avant-garde business ideas to our clients. We address clients living in across parts of the world with our 24/7 service availability.

More:
Rheumatoid Arthritis Stem Cell Therapy Market Future Innovation Strategies, Growth & Profit Analysis, Forecast by 2028 - The Cloud Tribune

To Read More: Rheumatoid Arthritis Stem Cell Therapy Market Future Innovation Strategies, Growth & Profit Analysis, Forecast by 2028 – The Cloud Tribune
categoriaBone Marrow Stem Cells commentoComments Off on Rheumatoid Arthritis Stem Cell Therapy Market Future Innovation Strategies, Growth & Profit Analysis, Forecast by 2028 – The Cloud Tribune | dataJune 20th, 2020
Read All

Dana-Farber Patient Recovering Well After Cancer and the Coronavirus | Dana-Farber – Dana-Farber Cancer Institute

By daniellenierenberg

Pam Dobay is a warrior. In the last three years, the 67-year-old has dealt with a cancer diagnosis and stem cell transplant before recently contracting the coronavirus.

None of it was easy, but today, Dobay is recovering at home. She says she cannot begin to express the gratitude she feels towards everyone who has cared for her, including her Dana-Farber care team and her family.

When this is all over, I want to show everyone at Dana-Farber what they did, and thank them for everything, says Dobay.

In February 2018, Dobay was diagnosed with myelofibrosis, a blood disorder in which the bone marrow is unable to produce healthy red blood cells. Dobays primary care physician first worried something wasnt right after her test results from routine blood work came back abnormal. Myelofibrosis is a precursor condition for leukemia, meaning it puts those who are diagnosed at a much higher chance of developing the disease.

Dobay, who lives in Holbrook, MA, was placed under the care of Corey Cutler, MD, MPH, medical director of the Adult Stem Cell Transplantation Program at Dana-Farber/Brigham and Womens Cancer Center. Initially, she was given blood transfusions to help her body compensate for the bone marrows inability to produce red blood cells. This treatment is not designed to be a permanent fix, despite being highly effective for a short period of time: Eventually, Dobay would need a bone marrow transplant.

In September 2018, just six months after her diagnosis, Dobay underwent a reduced-intensity transplant (sometimes referred to as a mini-transplant). Mini-transplant patients receive lower doses of chemotherapy than are used in a full-intensity transplant, and in general, receive no radiation therapy. The reduced-intensity procedure was developed for older patients and others who often cant tolerate the harsh side effects of full-intensity treatments.

The procedure still proved to be difficult for Dobay, who ended up in the intensive care unit (ICU) due to complications. This was a possibility her care team had prepared for, and slowly, her condition improved. While she still has some symptoms of chronic graft-versus-host disease (GVHD), she and her family including Robert Dobay, her husband of 45 years hoped this would be her toughest test.

In March 2020, Dobay started experiencing fevers, chills, and difficulty breathing three symptoms of the coronavirus. Dobays family called Cutler, who instructed them to immediately bring her to the nearest emergency room. She was initially treated at her local hospital, but after she tested positive for the coronavirus, the family pushed for her to be transported to Brigham and Womens Hospital.

The team at Dana-Farber encourages anyone who is experiencing symptoms associated with COVID-19 to report them right away. Even if you have a confirmed case of the coronavirus, there are measures in place to ensure you can receive the care thats safe for you, your care team, and other patients and staff members.

Because Dobay was a former bone marrow transplant recipient and has GVHD, she is immunocompromisedand was at an increased risk for developing severe symptoms due to COVID-19. Upon being admitted to the ICU at Brigham and Womens, her condition worsened, and she needed to be placed on a ventilator.

Due to visitor restrictions, the Dobays were not allowed to visit her in the hospital, so her husband called her care team every day to check in.

Dr. Cutler contacted Francisco Marty, MD, an infectious disease specialist in the Adult Stem Cell Transplantation Center at Dana-Farber/Brigham and Womens Cancer Center, to discuss Dobays care. Marty was the principal investigator of trials testing the antiviral drug remdesivir, and its ability to treat patients with COVID-19 pneumonia.At the time, it was unclear if it would help bone marrow transplant recipients.

Dobay became the first stem cell transplant patient at Brigham and Womens to receive the drug. A week after starting treatment her lung function improved, and she was able to come off the ventilator. However, other medical complications led to her being placed back on the ventilator and to remain in the intensive care unit for a couple of more weeks. Over time, she was once again taken off the ventilator, and in early May she was finally able to go home.

We were very happy that the remdesivir trials were open to all patients, including many of our cancer and bone marrow transplant patients at Dana-Farber, says Marty. The initial reports from the clinical trials have shown patients who receive remdesivir recover faster from COVID-19 pneumonia. As additional analyses from the trials are performed, we will be able to see more closely how remdesivir helped the cancer patients at Dana-Farber and elsewhere.

We were all terrified, but she is just incredibly strong, Robert Dobay says. We are so thankful for her care team who helped her get through this.

Dobay says she has regained most of her strength since returning home, and in addition to her physical therapy, she is once again doing squats, weightlifting, and sit-ups. She is also back to going on walks with her daughter and her dog.

Pam has such a strong will, and her supportive husband was a remarkably large part of her recovery, says Tricia Severns, ANP-BC, OCN, a nurse practitioner at Dana-Farber and a member of Dobays care team. The entire family is incredibly strong and supportive.

I feel really lucky to still be here, adds Dobay. I could not have gotten through all of this without my family. Wed do anything for one another.

Excerpt from:
Dana-Farber Patient Recovering Well After Cancer and the Coronavirus | Dana-Farber - Dana-Farber Cancer Institute

To Read More: Dana-Farber Patient Recovering Well After Cancer and the Coronavirus | Dana-Farber – Dana-Farber Cancer Institute
categoriaBone Marrow Stem Cells commentoComments Off on Dana-Farber Patient Recovering Well After Cancer and the Coronavirus | Dana-Farber – Dana-Farber Cancer Institute | dataJune 19th, 2020
Read All

Global Acute Myeloid Leukemia (AML) Therapeutics Market Revenue to Record Stable Growth Through COVID 19 Affected Period – Cole of Duty

By daniellenierenberg

Leukemia are a heterogeneous group of cancers affecting the bone marrow and White Blood Cells (WBC). Leukemia is characterized by the rapid increase of abnormal blood cells growth or blasts, resulting in a decrease in the numbers of healthy, normal fully modified blood cells, leading to the typical symptoms of bleeding, anemia, and high risk of infection. Leukemia can grow along either the myeloid or lymphoid stem cell lines, it depends on the effect of genetic and epigenetic mutations on the progression of pluripotent stem cells to the various lines of mature cells which then pass into the blood. The effected line, combined with the rate of action and growth of disease reflects the four types of leukemias- Acute Myeloid Leukemia (AML), chronic lymphoblastic leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia. AML: Acute Myeloid Leukemia, is a serious condition, its the most common leukemia suffered by adult people. According to a report from American Cancer Society, the average age for first diagnostic for AML is 64. With few days without treatment, AML develops fast, in duration of few weeks, the patient becomes severely ill. Due to its fast onset and acuteness in nature, there is no staging system for Acute Myeloid Leukemia (AML).The treatment for Acute Myeloid Leukemia (AML) has changed in last 4 decades.

Get Free Sample Copy With Impact Analysis Of COVID-19 Of Market Report @https://www.persistencemarketresearch.com/samples/16738

The drug approval process is difficult in AML, (many drugs have not been approved by USFDA, for instance Laromustine, Dacogen and Tipitarnib) efforts have been made to introduce new therapies in the AML market.

Primary drivers boosting the growth of acute myeloid leukemia (AML) therapeutics market are minimal but increased prevalence of acute myeloid leukemia (AML), increased drug approval rate for AML, classification of acute myeloid leukemia (AML) as an orphan disease. Over the forecast period, population of people over 65 year is anticipated to increase, which is another key driver for acute myeloid leukemia (AML) therapeutics market.

However, lack of targeted therapies in current acute myeloid leukemia (AML) therapeutics landscape, the drug difficult approval process in AML can hinder the growth of acute myeloid leukemia (AML) therapeutics market, but this restraint has opened an opportunity for key players to innovate acute myeloid leukemia (AML) therapeutics market.

The global acute myeloid leukemia (AML) therapeutics market is segmented on the basic of disease subtype, treatment type, end user and region.

Based on the disease subtype, the acute myeloid leukemia (AML) therapeutics market is segmented into the following:

Based on treatment type, the acute myeloid leukemia (AML) therapeutics market is segmented into the following:

Based on end user, the acute myeloid leukemia (AML) therapeutics market is segmented into the following:

The players in acute myeloid leukemia (AML) therapeutics market include Ambit Biosciences Corporation, Celgene Corporation, Cephalon Inc., Clavis Pharma ASA, Eisai Co. Ltd, Genzyme Corporation, and Sunesis Pharmaceuticals Inc., Abbvie Inc., Astellas Pharma Inc, CTI Biopharma Corp etc.

You Can Buy This PMR Healthcare Report From Here @https://www.persistencemarketresearch.com/checkout/16738

The global acute myeloid leukemia (AML) therapeutics market is anticipated to show lucrative growth owing to increased investment in innovative technologies by key players. Players in this market using various strategies to fuel their global footprint and to gain a competitive edge. Product pipelines, new product launches, agreements and collaborations, acquisitions, mergers and clinical trials are some key strategies applied from global players in recent years are anticipated to give a robust hike to the market in the forecast period.

Geographically, acute myeloid leukemia (AML) therapeutics market is segmented into regions viz. North America, Latin America, Europe, Asia Pacific and Japan, Middle East and Africa. North America is anticipated to be major contributor to this market accounting maximum percent of share in AML therapeutics market followed by Europe. Slow but constant growth in prevalence for AML in North America is anticipated to fuel the growth in acute myeloid leukemia (AML) therapeutics market. In Asia pacific region, China and India are anticipated to show high growth in acute myeloid leukemia (AML) therapeutics market due to new developments in healthcare infrastructure in the region.

Here is the original post:
Global Acute Myeloid Leukemia (AML) Therapeutics Market Revenue to Record Stable Growth Through COVID 19 Affected Period - Cole of Duty

To Read More: Global Acute Myeloid Leukemia (AML) Therapeutics Market Revenue to Record Stable Growth Through COVID 19 Affected Period – Cole of Duty
categoriaBone Marrow Stem Cells commentoComments Off on Global Acute Myeloid Leukemia (AML) Therapeutics Market Revenue to Record Stable Growth Through COVID 19 Affected Period – Cole of Duty | dataJune 19th, 2020
Read All

World Sickle Cell Day 2020: Know The Types, Symptoms, Causes And Treatment – NDTV

By daniellenierenberg

2020 World Sickle Cell Day: Symptoms of sickle cell can appear around 5 months of age

World Sickle Cell Day is observed on June 19. The day is meant to raise awareness about sickle cell disease, which is a group of disorders that affect haemoglobin, the molecule in red blood cells which deliver oxygen to cells throughout the body. People with this disorder have haemoglobin S, an atypical haemoglobin molecule which can distort red blood cells into a sickle or a crescent shape. This disease is a blood disorder which is inherited and passed down from parents to the child. In 2008, the UN General Assembly recognised sickle cell disease as a public health problem, and one of the world's foremost genetic diseases.

Symptoms of sickle cell disease usually appear around five months of age. The symptoms vary from person to person and change over time.

Symptoms of sickle cell disease can appear from two to five months of age. But in milder cases, the symptoms may appear till teenage.

Sickle cell disease can cause vision problemsPhoto Credit: iStock

Also read:These Iron-Packed Foods Can Combat Anemia And Other Health Problems

One can get infected with sickle cell disease if both parents have the problem gene and pass it on to their child.

1. HbSS or sickle cell anemia is a severe kind of sickle cell disease. It occurs when child inherits sickle cell gene from each parent.

2. HbSc occurs when one parents has sickle cell gene and the other has a gene from abnormal haemoglobin.

3. Hbs beta thalassemia occurs when sickle cell gene is passed from one parent, and beta-thalassemia is passed on from the other.

If only one parent has the problem gene, then the child will not have symptoms but will have the gene known as sickle cell trait.

Also read:Anemia During Pregnancy: Symptoms, Risk Factors And Prevention Steps Every Woman Must Know

Sickle cell can be detected in an infant during newborn screening process. In case of family history, it can be detected during pregnancy.

Bone marrow or stem cell transplant is the only permanent cure for sickle cell disease. Early detection and timely treatment can help in managing symptoms, offer relief from pain and prevent severe complications.

Apart from stem cell transplant, the symptoms can be managed with the help of periodic blood transfusion, pain killers, vaccinations and antibiotics.

Also read:6 Side-Effects Of Overuse Of Antibiotics And Home Remedies By Rujuta Diwekar That Can Be As Effective

Disclaimer: This content including advice provides generic information only. It is in no way a substitute for qualified medical opinion. Always consult a specialist or your own doctor for more information. NDTV does not claim responsibility for this information.

More here:
World Sickle Cell Day 2020: Know The Types, Symptoms, Causes And Treatment - NDTV

To Read More: World Sickle Cell Day 2020: Know The Types, Symptoms, Causes And Treatment – NDTV
categoriaBone Marrow Stem Cells commentoComments Off on World Sickle Cell Day 2020: Know The Types, Symptoms, Causes And Treatment – NDTV | dataJune 19th, 2020
Read All

Olive’s stem cell donation makes impact off the field – Bryant University Bulldogs

By daniellenierenberg

SMITHFIELD, R.I. Stephen Olive was one of nearly 100 Bryant Football players that took part in the Andy Talley Bone Marrow Foundation's "Get in the Game. Save a Life" program in March of 2018.

A simple cheek swab was all it took to be entered into the database and possibly become a donor.

It wasn't the first time the Bryant Football team had taken part in the program. Taylor Janoskie, a four-year member of the football team and a member of the Class of 2016, was one of many to get their cheek swabbed in 2013. Seeing the post on Twitter in 2018, Janoskie reached out to inform the football program that he had matched and had donated bone marrow in February of 2017, helping save the life of a 52-year old man with two children.

"If anybody that got swabbed today is a match," Janoskie wrote, "tell them without hesitation to donate because saving someone's life is an incredible feeling."

Olive matched and three years later, on May 6, he made a donation to help save the life of a patient with Leukemia.

A hulking 6-6, 285 pounds, Olive couldn't donate bone marrow due to back surgery he underwent as a freshman with the Bulldogs. Instead, Olive donated stem cells. He received shots to overproduce stem cells for five days, culminating in his visit to Roger Williams Hospital in Providence to complete the donation.

"I donated because this man's life depended on it," Olive said. "Very rarely do people have the opportunity to be able to make this kind of a difference in someone's life."

Going to the hospital was made a bit more difficult, however, due to the covid-19 pandemic. Olive had to put his fears behind him.

"Cancer wasn't going to put itself on hold just for the pandemic," Olive said. "It's still out there killing people, so I had to swallow any fear I had of Coronavirus and just do it."

The donation took five hours and included a pre-donation physical and a central line into Olive's neck.

It was during his physical that Olive received another sign that he was doing the right thing. His doctor had a brother who passed away waiting for this type of donation.

"My doctor didn't believe people just go out and save lives, he believed God put people in the right place at the right time and uses them as tools to save people," Olive said. "Very rarely do you get to be that tool."

For more information about the Andy Talley Bone Marrow Foundation, click here.

See original here:
Olive's stem cell donation makes impact off the field - Bryant University Bulldogs

To Read More: Olive’s stem cell donation makes impact off the field – Bryant University Bulldogs
categoriaBone Marrow Stem Cells commentoComments Off on Olive’s stem cell donation makes impact off the field – Bryant University Bulldogs | dataJune 18th, 2020
Read All

Worldwide Stem Cell Therapy Industry to 2027 – Growth in the Global Healthcare Market Presents Opportunities – PRNewswire

By daniellenierenberg

DUBLIN, June 18, 2020 /PRNewswire/ -- The "Stem Cell Therapy Market to 2027 - Global Analysis and Forecasts by Type; Treatment; Application; End User, and Geography" report has been added to ResearchAndMarkets.com's offering.

The stem cell therapy market was valued at US$ 1,534.55 million in 2019 and is estimated to reach US$ 5,129.66 million by 2027; it is expected to grow at a CAGR of 16.7% from 2020 to 2027.

The increasing awareness related to the stem cells therapy in effective disease management and growing demand for regenerative medicines are the key factor driving the stem cell therapy market. However, high cost related of the stem cell therapy limits the growth of the market.

Stem cell research has been widely investigated globally for various medical applications, especially for the treatment of humans. This raises the importance of creating public awareness about stem cell research and its clinical potential. The main role of stem cells is in the replacement of dying cells and reconstruction of damaged tissues. Based on the extensive stem cell research, many scientists have claimed that these cells could probably be used in the treatment of various diseases, including cancer and cardiovascular disease.

There is a large number of potential treatment procedures that are undergoing clinical trials, and a notably few stem cell therapies have won FDA (i.e., US -Food and Drug Administration) approval for clinical usage. For instance, in 2019, the FDA approved Fedratinib for the first-line treatment for myelofibrosis. Moreover, stem cell therapies are widely used in bone marrow transplantation, and these therapies have benefited thousands of people suffering from leukemia. Hematopoietic stem cells are used for treating more than 80 medical diseases, including immune system disorders, blood disorders, neurological disorders, metabolic disorders, genetic disorders, and several types of cancers, such as leukemia and lymphoma; this is also likely to boost the demand for this treatment procedure during the forecast period. Researchers are further investigating the use of stem cell therapies in the treatment of autoimmune disorders.

The global stem cell therapy market has been segmented on the basis of type, treatment, application type, and end user. Based on type, the market has been segmented into adult stem cell therapy, induced pluripotent stem cell therapy, embryonic stem cell therapy, and others. The adult stem cell therapy held the largest share of the market in 2019; however, induced pluripotent stem cell therapy is estimated to register the highest CAGR in the market during the forecast period. Based on treatment, the stem cell therapy market has been segmented into allogeneic and autologous. The allogeneic segment held a larger share of the market in 2019; however, the market for the autologous segment is expected to grow at a higher CAGR during the forecast period.

Reasons to Buy:

Key Topics Covered:

1. Introduction1.1 Scope of the Study1.2 Report Guidance1.3 Market Segmentation1.3.1 Global Stem Cell Therapy Market - By Type1.3.2 Global Stem Cell Therapy Market - By Treatment1.3.3 Global Stem Cell Therapy Market - By Application1.3.4 Global Stem Cell Therapy Market - By End User1.3.5 Global Stem Cell Therapy Market - By Geography

2. Stem Cell Therapy Market - Key Takeaways

3. Research Methodology3.1 Coverage3.2 Secondary Research3.3 Primary Research

4. Stem Cell Therapy - Market Landscape4.1 Overview4.2 PEST Analysis4.2.1 North America4.2.2 Europe4.2.3 Asia Pacific4.2.4 Middle East & Africa4.2.5 South and Central America4.3 Expert Opinion

5. Stem Cell Therapy Market - Key Market Dynamics5.1 Market Drivers5.1.1 Increasing Awareness Related to the Stem Cells Therapy in Effective Disease Management5.1.2 Growing Demand For Regenerative Medicines5.1.3 Growing Cancer Prevalence Across The Globe5.2 Market Restraints5.2.1 High Cost Related with Stem Cell Therapy5.3 Market Opportunities5.3.1 Growth in the Global Healthcare Market5.4 Future Trends5.4.1 Research Activities and Product Innovations5.5 Impact Analysis

6. Stem Cell Therapy Market - Global Analysis6.1 Global Stem Cell Therapy Market Revenue Forecast And Analysis6.2 Global Stem Cell Therapy Market, By Geography - Forecast And Analysis6.3 Market Positioning of Key Players

7. Global Stem Cell Therapy Market Analysis- by Type7.1 Overview7.2 Stem Cell Therapy Market Revenue Share, by Type (2019 and 2027)7.3 Adult Stem Cell Therapy7.3.1 Overview7.3.2 Adult Stem Cell Therapy : Stem Cell Therapy Market - Revenue and Forecast to 2027 (US$ Million)7.3.3 Hematopoietic Stem Cell Therapy7.3.3.1 Overview7.3.3.2 Hematopoietic Stem Cell Therapy: Stem Cell Therapy Market - Revenue and Forecast to 2027 (US$ Million)7.3.4 Umbilical Cord Stem Cell Therapy7.3.4.1 Overview7.3.4.2 Umbilical Cord Stem Cell Therapy: Stem Cell Therapy Market - Revenue and Forecast to 2027 (US$ Million)7.3.5 Neuronal Stem Cell Therapy7.3.5.1 Overview7.3.5.2 Neuronal Stem Cell Therapy: Stem Cell Therapy Market - Revenue and Forecast to 2027 (US$ Million)7.3.6 Mesenchymal Stem Cell7.3.6.1 Overview7.3.6.2 Mesenchymal Stem Cell: Stem Cell Therapy Market - Revenue and Forecast to 2027 (US$ Million)7.4 Induced Pluripotent Stem Cell Therapy7.4.1 Overview7.4.2 Induced Pluripotent Stem Cell Therapy: Stem Cell Therapy Market - Revenue and Forecast to 2027 (US$ Million)7.4.3 Induced Pluripotent Stem Cell Therapy: Stem Cell Therapy Market - Revenue and Forecast to 2027 (US$ Million)7.5 Embryonic Stem Cell Therapy7.5.1 Overview7.5.2 Embryonic Stem Cell Therapy: Stem Cell Therapy Market - Revenue and Forecast to 2027 (US$ Million)7.6 Other Stem Cell Therapy7.6.1 Overview7.6.2 Other Stem Cell Therapy: Stem Cell Therapy Market - Revenue and Forecast to 2027 (US$ Million)

8. Stem Cell Therapy Market Analysis- by Treatment8.1 Overview8.2 Stem Cell Therapy Market, by Treatment 2019 and 2027 (%)8.3 Allogeneic8.3.1 Overview8.3.2 Allogeneic: Stem Cell Therapy Market - Revenue and Forecast to 2027 (US$ Million)8.4 Autologous8.4.1 Overview8.4.2 Autologous: Stem Cell Therapy Market - Revenue and Forecast to 2027 (US$ Million)

9. Stem Cell Therapy Market Analysis - by Application9.1 Overview9.2 Stem Cell Therapy Market Revenue Share, by Application (2019 and 2027)9.3 Musculoskeletal9.3.1 Overview9.3.2 Musculoskeletal: Stem Cell Therapy Market - Revenue and Forecast to 2027 (US$ Million)9.4 Dermatology9.4.1 Overview9.4.2 Dermatology: Stem Cell Therapy Market - Revenue and Forecast to 2027 (US$ Million)9.5 Cardiology9.5.1 Overview9.5.2 Cardiology: Stem Cell Therapy Market - Revenue and Forecast to 2027 (US$ Million)9.6 Drug Discovery and Development9.6.1 Overview9.6.2 Drug Discovery and Development: Stem Cell Therapy Market - Revenue and Forecast to 2027 (US$ Million)9.7 Other Applications9.7.1 Overview9.7.2 Other Applications: Stem Cell Therapy Market - Revenue and Forecast to 2027 (US$ Million)

10. Stem Cell Therapy Market Analysis- by End User10.1 Overview10.2 Stem Cell Therapy Market, by End User 2019 and 2027 (%)10.3 Academic & Research Institutes10.3.1 Overview10.3.2 Academic & Research Institutes: Stem Cell Therapy Market - Revenue and Forecast to 2027 (US$ Million)10.4 Hospitals & Specialty Clinics10.4.1 Overview10.4.2 Hospitals & Specialty Clinics : Stem Cell Therapy Market - Revenue and Forecast to 2027 (US$ Million)

11. Stem Cell Therapy Market - Geographic Analysis11.1 North America: Stem Cell Therapy Market11.2 Europe: Stem Cell Therapy Market11.3 Asia Pacific: Stem Cell Therapy Market11.4 Middle East & Africa: Stem Cell Therapy Market11.5 South and Central America: Stem Cell Therapy Market

12. Stem Cell Therapy Market -Industry Landscape12.1 Overview12.2 Growth Strategies In The Stem Cell Therapy Market, 2015-201912.3 Organic Growth Strategies12.3.1 Overview12.4 Inorganic Growth Strategies12.4.1 Overview

13. COMPANY PROFILES13.1 MEDIPOST13.1.1 Key Facts13.1.2 Business Description13.1.3 Products and Services13.1.4 Financial Overview13.1.5 SWOT Analysis13.1.6 Key Developments13.2 Pharmicell Co., Inc.13.3 RichSource13.4 BioTime Inc. (Lineage Cell Therapeutics, Inc.)13.5 Mesoblast Limited13.6 Holostem Terapie Avanzate Srl13.7 U.S. Stem Cell, Inc.13.8 Caladrius Biosciences, Inc.13.9 TiGenix NV13.10 AlloSource

For more information about this report visit https://www.researchandmarkets.com/r/m8jwr5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Read more from the original source:
Worldwide Stem Cell Therapy Industry to 2027 - Growth in the Global Healthcare Market Presents Opportunities - PRNewswire

To Read More: Worldwide Stem Cell Therapy Industry to 2027 – Growth in the Global Healthcare Market Presents Opportunities – PRNewswire
categoriaBone Marrow Stem Cells commentoComments Off on Worldwide Stem Cell Therapy Industry to 2027 – Growth in the Global Healthcare Market Presents Opportunities – PRNewswire | dataJune 18th, 2020
Read All

Anonymous US stem cell donor saves the life of Norwich girl – Eastern Daily Press

By daniellenierenberg

PUBLISHED: 18:00 18 June 2020

Simon Parkin

Imogen Roe returned home to Norfolk after 100 days in isolation in hospital. Picture: Anna Dagless

Archant

A nine-year-old girls life was saved by an anonymous blood stem cell donor after a brave battle with leukaemia in which she asked her mum am I going to die?

Email this article to a friend

To send a link to this page you must be logged in.

Imogen Roe, from Norwich, had just turned six when she was treated for routine tonsillitis. But her worried parents, Anna and Dean, took her back to the doctors when they noticed abnormal bruising and a rash on her body.

They were told to take Imogen to their local hospital, and were soon confronted with the devastating diagnosis.

Mum Anna, 38, said: We suspected it was a reaction to penicillin at worst. But within an hour of being at our local hospital we were told it was leukaemia, and within 24 hours we were in Addenbrookes Hospital. It all happened so fast, I dont remember feeling much other than panic and shock.

Because of the aggressiveness of her leukaemia, young Imogen began two-and-a-half years of high dosage chemotherapy.

Anna said: Imogen was such a trouper, and very co-operative which made for a very easy patient!

I cannot believe how well she just got on with things; cannulas, nose tubes, general anaesthetics, surgery - even though at times she has been very scared about procedures.

During this time the family was divided, with Imogen and her mum in Addenbrookes, whilst Dad Dean, 39, stayed at home with their other two children, Imogens twin sister Charlotte, and older brother Liam, 11.

MORE: Esm, three, wins 19-month cancer battle but cannot celebrate traditional bell ringingIn January 2019, almost three years after her diagnosis, young Imogen finished her chemo and rang her end of treatment bell to huge applause from doctors, nurses, hospital staff - and her proud, but exhausted parents.

The young family were finally able to get their lives back on track, but unfortunately more heartbreaking news was just around the corner.

Anna said: It was July 2019, almost three years to the day since Imogens original diagnosis, and we had just bought a puppy and booked a family holiday abroad with friends. Then we noticed that familiar rash on her legs, and were told to bring her to hospital.

After undergoing tests, doctors confirmed the worst Imogen had relapsed and the leukaemia had come back.

Doctors revealed that, in addition to further chemotherapy, Imogens best chance of beating the disease was to have a blood stem cell transplant from a matching donor.

Imogens siblings were both tested, and the family were delighted to be told that her sister Charlotte was a 100% match.

However, after further tests, they were confronted with shocking news after a decade of thinking Charlotte and Imogen were non-identical twins, they were in fact identical, which meant that Charlotte would not be a suitable donor after all.

Doctors began looking for Imogens potential lifesaver elsewhere searching the worldwide register of potential blood stem cell donors, hoping to find a perfect stranger who happens to be Imogens genetic twin.

With Imogens life hanging in the balance a match was found. Cord blood, donated by a new mother in the USA and frozen nine years prior, was a perfect match for Imogen. This was the only suitable match for Imogen anywhere in the world.

MORE: How support, prayers and herbal rememdies helped nurse beat coronavirusAs the frozen cord blood was prepared to be flown from America to the UK, Imogen had 10 days of conditioning treatment prior to transplant; four days of extremely strong chemotherapy, and then eight sessions of total body irradiation, to prepare her to receive the new blood stem cells.

This is an incredibly vulnerable point in any treatment plan. The new marrow should, over a few weeks, start to regenerate within the body, but for Imogen, after 36 days of daily blood tests, there was still no sign of any new cells being manufactured.

Her mum said: It was a very serious situation as without any white cells to fight off infection, Imogen was extremely vulnerable even from her isolation room, as you can pick up bugs from your own body.

Ten days post transplant she got an infection, and she went into septic shock. This led to several serious viruses, a chest infection, and bacterial infection. We had the rapid response team on standby for a transfer to intensive care, but Imogen pulled through, just as her dad arrived after making the five hour journey from our home.

Imogen remained in isolation in Bristol for 99 days, fighting off multiple infections, whilst dad Dean travelled the five hours back and forth between home and the hospital to bring Anna clean clothes and supplies.

Finally, Imogen was transferred back to Addenbrookes to continue her recovery one step closer to home.

MORE: Wife of rugby star launches new business two years after being given a month to liveOn March 13, in the midst of the Covid-19 pandemic, she was finally discharged and returned home to her mum, dad and siblings, who are now all self isolating.

It had been 170 days since she, or mum Anna, had seen any extended family.

Speaking about Imogens anonymous donor, Anna said the family were acutely aware of the luck involved in finding a match.

She said: Imogen had just one match. There are some people we know through our time in hospitals who were fortunate enough to have a selection of matches, and many others are still waiting for a match that may never come.

If you are aged between 17 and 55 and in general good health, you take the first step to register as a blood stem cell donor by registering for a home swab kit at dkms.org.uk

If you value what this story gives you, please consider supporting the Eastern Daily Press. Click the link in the yellow box below for details.

Continued here:
Anonymous US stem cell donor saves the life of Norwich girl - Eastern Daily Press

To Read More: Anonymous US stem cell donor saves the life of Norwich girl – Eastern Daily Press
categoriaBone Marrow Stem Cells commentoComments Off on Anonymous US stem cell donor saves the life of Norwich girl – Eastern Daily Press | dataJune 18th, 2020
Read All

Rare Hematology Treatment Market Analysis 2020 Along with Research Report 2026 – Cole of Duty

By daniellenierenberg

The Latest Study on Rare Hematology Treatment Market Perspective, Comprehensive Analysis along with Major Segments and Forecast, 2020-2026. The Rare Hematology Treatment Market report is a valuable source of data for business strategists. It provides the industry overview with market growth analysis with a historical & futuristic perspective for the following parameters; cost, revenue, demands, and supply data (as applicable). The report explores the current outlook in global and key regions from the perspective of players, countries, product types, and end industries. This Rare Hematology Treatment Market study provides comprehensive data that enhances the understanding, scope, and application of this report.

Top Companies: Takeda, Biogen, Novo Nordisk, Bayer, CSL Behring, Pfizer, PRA Health Sciences, Celgene, Alexion Pharma, Amgen

Get a sample copy Of this Report:

https://www.marketinsightsreports.com/reports/06122088250/global-rare-hematology-treatment-market-size-status-and-forecast-2020-2026/inquiry?Mode=31

Overview: Blood develops from hematopoietic stem cells (HSC) and formation takes place in the bone marrow through a sequence of the regulated process known as hematopoiesis. Blood contains component such as plasma, RBS, WBC, and platelets. Blood disorders include bleeding disorders such as hemophilia, blood clots; blood cancers (leukemia, lymphoma, and myeloma). When the normal process of the blood development fails, abnormal blood cell type is produced, which causes blood cancer and other blood disorders. The rare hematological disease includes anemia-type red blood cell conditions, white blood cell dysfunctions, immuno-disorders and other platelet-based abnormalities.

Global Rare Hematology Treatment Market Split By Product Type And Applications:

This report segments the global Rare Hematology Treatment Market on the basis ofTypesare:

Plasma Derived FactorsRecombinant Factors

On the basis ofApplication, the Global Rare Hematology Treatment Market is segmented into:

Hemophilia AHemophilia BVon Wilebrand DiseaseOthers

Regional Analysis: For a comprehensive understanding of market dynamics, the global Rare Hematology Treatment Market is analyzed across key geographies namely: United States, China, Europe, Japan, Middle East & Africa, India, and others. Each of these regions is analyzed on the basis of market findings across major countries in these regions for a macro-level understanding of the market.

Explore Full Report With Detailed TOC Here:

https://www.marketinsightsreports.com/reports/06122088250/global-rare-hematology-treatment-market-size-status-and-forecast-2020-2026?Mode=31

Influence of the Rare Hematology Treatment Market report:-Comprehensive assessment of all opportunities and risks in the Rare Hematology Treatment Market. Rare Hematology Treatment Market recent innovations and major events.-A detailed study of business strategies for the growth of the Rare Hematology Treatment Market-leading players.-Conclusive study about the growth plot of the Rare Hematology Treatment market for forthcoming years.-In-depth understanding of Rare Hematology Treatment Market -particular drivers, constraints, and major micro markets.-Favorable impression inside vital technological and market latest trends striking the Rare Hematology Treatment Market.

What are the market factors that are explained in the report?

-Key Strategic Developments: The study also includes the key strategic developments of the market, comprising R&D, new product launch, M&A, agreements, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a global and regional scale.

-Key Market Features: The report evaluated key market features, including revenue, price, capacity, capacity utilization rate, gross, production, production rate, consumption, import/export, supply/demand, cost, market share, CAGR, and gross margin. In addition, the study offers a comprehensive study of the key market dynamics and their latest trends, along with pertinent market segments and sub-segments.

Analytical Tools: The Global Rare Hematology Treatment Market report includes the accurately studied and assessed data of the key industry players and their scope in the market by means of a number of analytical tools. The analytical tools such as Porters five forces analysis, feasibility study, and investment return analysis have been used to analyze the growth of the key players operating in the market.

Finally, The Rare Hematology Treatment Market report is the believable source for gaining Market research that will exponentially accelerate your business. The report gives the principle locale, economic situations with the item value, benefit, limit, generation, supply, request, and Market development rate and figure, and so on. This report additionally Present a new task SWOT examination, speculation attainability investigation, and venture return investigation.

We also offer customization on reports based on specific client requirement:

1-Freecountry level analysis forany 5 countriesof your choice.

2-FreeCompetitive analysis of any market players.

3-Free 40 analyst hoursto cover any other data points

About Us:MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information, and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact Us:

Irfan Tamboli (Head of Sales) Market Insights Reports

Phone: + 1704 266 3234 | +91-750-707-8687

[emailprotected]|[emailprotected]

Read more:
Rare Hematology Treatment Market Analysis 2020 Along with Research Report 2026 - Cole of Duty

To Read More: Rare Hematology Treatment Market Analysis 2020 Along with Research Report 2026 – Cole of Duty
categoriaBone Marrow Stem Cells commentoComments Off on Rare Hematology Treatment Market Analysis 2020 Along with Research Report 2026 – Cole of Duty | dataJune 18th, 2020
Read All

Global Bone Marrow-Derived Stem Cells (BMSCS) Market (COVID 19 Impact Analysis) Data Highlighting Major Vendors, Promising Regions, Anticipated Growth…

By daniellenierenberg

Global Bone Marrow-Derived Stem Cells (BMSCS) Market research report delivers comprehensive analysis of the market structure along with estimations of the various segments and sub-segments of the market. This study also analyzes the market status, market share, growth rate, sales volume, future trends, market drivers, market restraints, revenue generation, opportunities and challenges, risks and entry barriers, sales channels, and distributors. The company profiles of all the chief and dominating market players and brands who are taking steps such as product launches, joint ventures, mergers and acquisitions are mentioned in the report. With the use of SWOT analysis and Porters Five Forces analysis which are two of the standard, prominent and full-proof methods, this Global Bone Marrow-Derived Stem Cells (BMSCS) Market report is been framed.

Global Bone Marrow-Derived Stem Cells (BMSCS) Market By Service Type (Sample Preservation and Storage, Sample Analysis, Sample Processing, Sample Collection and Transportation), Application (Personalized Banking Applications, Research Applications, Clinical Applications), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa), Market Trends and Forecast to 2027

By providing an absolute overview of the market, Global Bone Marrow-Derived Stem Cells (BMSCS) Market report covers various aspects of market analysis, product definition, market segmentation, key developments, and the existing vendor landscape. Such market insights can be accomplished with this comprehensive Global Bone Marrow-Derived Stem Cells (BMSCS) Market research report which takes into account all the aspects of current and future market. The report provides wide-ranging analysis of the market structure along with the estimations of the various segments and sub-segments of the market. This Global Bone Marrow-Derived Stem Cells (BMSCS) Market research report delivers an analytical measurement of the main challenges faced bythe business currently and in the upcoming years.

Bone marrow-derivedstem cells(BMSCS) marketis expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to growing at a CAGR of 10.4% in the above-mentioned forecast period. Increasing awareness regarding the benefits associates with the preservation of bone marrow derived stem cells will boost the growth of the market.

Get Sample Report + All Related Graphs & Charts @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-bone-marrow-derived-stem-cells-bmscs-market

The major players covered in the bone marrow-derived stem cells (BMSCS) market report are CBR Systems, Inc, Cordlife Sciences India Pvt. Ltd., Cryo-Cell International, Inc.ESPERITE N.V., LifeCell International Pvt. Ltd., StemCyte India Therapeutics Pvt. Ltd, PerkinElmer Inc, Global Cord Blood Corporation., Smart Cells International Ltd., Vita 34 among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Some of the factors such as introduction of novel technologies for the preservation of stem cells and their storage, surging investment that will help in research activities leading to stem cells benefits, adoption of hemotopoietic stem cell transplantation system will accelerate the growth of the bone marrow-derived stem cells (BMSCS) market in the forecast period of 2020-2027. Various factors that will create opportunities in the bone marrow-derived stem cells (BMSCS) market are increasing occurrences of various diseases along with rising applications in emerging economies.

Large cost of operation and strict regulatory framework will restrict the growth of bone marrow-derived stem cells (BMSCS) market in the above mentioned forecast period. Ethical concern leading to stem cells will become the biggest challenge in the market growth.

Global Bone Marrow-Derived Stem Cells (BMSCS) Market By Service Type (Sample Preservation and Storage, Sample Analysis, Sample Processing, Sample Collection and Transportation), Application (Personalized Banking Applications, Research Applications, Clinical Applications), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa), Market Trends and Forecast to 2027

Global Bone Marrow-Derived Stem Cells (BMSCS) Market Scope and Market Size

Bone marrow-derivedstem cells(BMSCS) market is segmented on the basis of service type and application. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Thisbonemarrow-derived stem cells (BMSCS) market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on bone marrow-derived stem cells (BMSCS) market contactData Bridge Market Researchfor anAnalyst Brief, our team will help you take an informed market decision to achieve market growth.

Grab Your Report at an Impressive 30% Discount! Please click Here @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-bone-marrow-derived-stem-cells-bmscs-market

Bone Marrow-Derived Stem Cells (BMSCS) Market Country Level Analysis

Bone marrow-derivedstem cells(BMSCS) market is analysed and market size insights and trends are provided by country, service type and application as referenced above.

The country section of the bone marrow-derivedstem cells(BMSCS) market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

Bone marrow-derived stem cells (BMSCS) market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipments, installed base of different kind of products for bone marrow-derived stem cells (BMSCS) market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the bone marrow-derived stem cells (BMSCS) market. The data is available for historic period 2010 to 2018.

For More Insights Get Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-bone-marrow-derived-stem-cells-bmscs-market

Key Highlights of Report

Competitive Landscape and Bone Marrow-Derived Stem Cells (BMSCS) Market Share Analysis

Bone marrow-derived stem cells (BMSCS) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to bone marrow-derived stem cells (BMSCS) market.

Get Registered For Digital Conference @https://www.databridgemarketresearch.com/digital-conference/future-of-healthcare-robotics?pm

About Data Bridge Market Research:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

Read more from the original source:
Global Bone Marrow-Derived Stem Cells (BMSCS) Market (COVID 19 Impact Analysis) Data Highlighting Major Vendors, Promising Regions, Anticipated Growth...

To Read More: Global Bone Marrow-Derived Stem Cells (BMSCS) Market (COVID 19 Impact Analysis) Data Highlighting Major Vendors, Promising Regions, Anticipated Growth…
categoriaBone Marrow Stem Cells commentoComments Off on Global Bone Marrow-Derived Stem Cells (BMSCS) Market (COVID 19 Impact Analysis) Data Highlighting Major Vendors, Promising Regions, Anticipated Growth… | dataJune 17th, 2020
Read All

Stem Cell Therapy Market to 2027 – Global Analysis and Forecasts – ResearchAndMarkets.com – Yahoo Finance

By daniellenierenberg

The "Stem Cell Therapy Market to 2027 - Global Analysis and Forecasts by Type; Treatment; Application; End User, and Geography" report has been added to ResearchAndMarkets.com's offering.

The stem cell therapy market was valued at US$ 1,534.55 million in 2019 and is estimated to reach US$ 5,129.66 million by 2027; it is expected to grow at a CAGR of 16.7% from 2020 to 2027.

The increasing awareness related to the stem cells therapy in effective disease management and growing demand for regenerative medicines are the key factor driving the stem cell therapy market. However, high cost related of the stem cell therapy limits the growth of the market.

Stem cell research has been widely investigated globally for various medical applications, especially for the treatment of humans. This raises the importance of creating public awareness about stem cell research and its clinical potential. The main role of stem cells is in the replacement of dying cells and reconstruction of damaged tissues. Based on the extensive stem cell research, many scientists have claimed that these cells could probably be used in the treatment of various diseases, including cancer and cardiovascular disease.

There is a large number of potential treatment procedures that are undergoing clinical trials, and a notably few stem cell therapies have won FDA (i.e., US -Food and Drug Administration) approval for clinical usage. For instance, in 2019, the FDA approved Fedratinib for the first-line treatment for myelofibrosis. Moreover, stem cell therapies are widely used in bone marrow transplantation, and these therapies have benefited thousands of people suffering from leukemia. Hematopoietic stem cells are used for treating more than 80 medical diseases, including immune system disorders, blood disorders, neurological disorders, metabolic disorders, genetic disorders, and several types of cancers, such as leukemia and lymphoma; this is also likely to boost the demand for this treatment procedure during the forecast period. Researchers are further investigating the use of stem cell therapies in the treatment of autoimmune disorders.

The global stem cell therapy market has been segmented on the basis of type, treatment, application type, and end user. Based on type, the market has been segmented into adult stem cell therapy, induced pluripotent stem cell therapy, embryonic stem cell therapy, and others. The adult stem cell therapy held the largest share of the market in 2019; however, induced pluripotent stem cell therapy is estimated to register the highest CAGR in the market during the forecast period. Based on treatment, the stem cell therapy market has been segmented into allogeneic and autologous. The allogeneic segment held a larger share of the market in 2019; however, the market for the autologous segment is expected to grow at a higher CAGR during the forecast period.

Reasons to Buy:

Market Dynamics

Drivers

Restraints

Opportunities

Future Trends

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/kn7iuy

View source version on businesswire.com: https://www.businesswire.com/news/home/20200615005447/en/

Contacts

ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

Read more from the original source:
Stem Cell Therapy Market to 2027 - Global Analysis and Forecasts - ResearchAndMarkets.com - Yahoo Finance

To Read More: Stem Cell Therapy Market to 2027 – Global Analysis and Forecasts – ResearchAndMarkets.com – Yahoo Finance
categoriaBone Marrow Stem Cells commentoComments Off on Stem Cell Therapy Market to 2027 – Global Analysis and Forecasts – ResearchAndMarkets.com – Yahoo Finance | dataJune 17th, 2020
Read All

Healthcare innovations making waves in 2020 – Crawley Observer

By daniellenierenberg

The speed of change is fascinating

As we head into the 2020s, tech developers and medical scientists are working hard to ensure that we stay healthy and well-cared for, for as long as possible. Here are some of the big healthcare innovations making waves at the moment.

Artificial blood has been proposed for a number of years, but it is only recently that it has gained any sort of traction in medical circles. The science behind it is simple to understand while no doubt actually being incredibly complex. Artificial blood does not seek to replace blood entirely but instead to supplement red blood cells in the body, to carry oxygen where it needs to be delivered.

These blood cells are called artificial as they are generated in a lab environment instead of a human body and are grown from stem cells. Researchers typically use hematopoietic stem cells taken from bone marrow for growing such cells. With blood donation dropping, this could be a timely solution to support healthcare professionals alongside blood donation drives.

Blindness is a massive issue no matter where you live on the planet. In particular, corneal blindness is the fourth most common blindness in the world. However, there is now a solution that is cheap and easy to deliver, and that could make a massive difference to many people.

Many are now coming forward to support medical staff in their endeavours in this sector. Tej and Wendy Kohli are key voices in creating help here. Following other charitable givers like Bill and Melissa Gates and Warren Buffett, it is clear that input from top figures like this is crucial in supporting a cause and seeing it develop into a system that could genuinely make a difference.

The ability to use genetic information to come up with a treatment plan for a patient is a precise art. However, research into the world of genomics is making this a much more viable method of treatment than it has previously.

The scope for this is massive. So much of our response to certain treatments can be bound up in our genetics and research here could change medicine forever. With setbacks like organ transplant rejection and gene mutation still having a major impact on medicine as a whole, it is incredibly important that researchers work to find a solution that works around these issues. Comprehensive and detailed genomics might be it.

All three of these areas have seen some massive leaps forward in the past month. No matter what, focus needs to be kept on these key areas in the future. Only then will we see some massive improvements that could shape our healthcare for the better. These developments could lead to the complex becoming the norm in worldwide healthcare.

Developments made today might one day be celebrated as pioneering breakthroughs that helped to transform healthcare and the lives of humanity.

Read more from the original source:
Healthcare innovations making waves in 2020 - Crawley Observer

To Read More: Healthcare innovations making waves in 2020 – Crawley Observer
categoriaBone Marrow Stem Cells commentoComments Off on Healthcare innovations making waves in 2020 – Crawley Observer | dataJune 17th, 2020
Read All

Hematopoietic Stem Cell Transplantation (HSCT) Market Segments, Opportunity, Growth and Forecast by End-use Idustry 2020-2026 – Cole of Duty

By daniellenierenberg

Hematopoietic Stem Cell Transplantation (HSCT) Market report provide the COVID19 Outbreak Impact analysis of key factors influencing the growth of the market Size (Production, Value and Consumption). This Hematopoietic Stem Cell Transplantation (HSCT) industry splits the breakdown (data status 2014-2020 and Six years forecast 2020-2026), by manufacturers, region, type and application. This study also analyses the Hematopoietic Stem Cell Transplantation (HSCT) market Status, Market Share, Growth Rate, Future Trends, Market Drivers, Opportunities and Challenges, Risks and Entry Barriers, Sales Channels, Distributors and Porters Five Forces Analysis.

Hematopoietic Stem Cell Transplantation (HSCT) Market competitive landscapes provides details by topmost manufactures like (Regen Biopharma Inc, China Cord Blood Corp, CBR Systems Inc, Escape Therapeutics Inc, Cryo-Save AG, Lonza Group Ltd, Pluristem Therapeutics Inc, ViaCord Inc), including Capacity, Production, Price, Revenue, Cost, Gross, Gross Margin, Growth Rate, Import, Export, Market Share and Technological Developments

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures)of Hematopoietic Stem Cell Transplantation (HSCT)[emailprotected]https://www.researchmoz.us/enquiry.php?type=S&repid=2276986

Hematopoietic Stem Cell Transplantation (HSCT) Market Competition by Manufacturers (2020 2026): Hematopoietic Stem Cell Transplantation (HSCT) Market Share of Top 3 and Top 5 Manufacturers, Hematopoietic Stem Cell Transplantation (HSCT) Market by Capacity, Production and Share by Manufacturers, Revenue and Share by Manufacturers, Average Price by Manufacturers By Market, Manufacturers Manufacturing Base Distribution, Sales Area, Product Type, Market Competitive Situation and Trends, Market Concentration Rate.

Scope of Hematopoietic Stem Cell Transplantation (HSCT) Market:In 2019, the market size of Hematopoietic Stem Cell Transplantation (HSCT) is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.

In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Hematopoietic Stem Cell Transplantation (HSCT).

On the basis of product type, this report displays the shipments, revenue (Million USD), price, and market share and growth rate of each type.

Allogeneic Autologous

On the basis on the end users/applications,this report focuses on the status and outlook for major applications/end users, shipments, revenue (Million USD), price, and market share and growth rate foreach application.

Peripheral Blood Stem Cells Transplant (PBSCT) Bone Marrow Transplant (BMT) Cord Blood Transplant (CBT)

Do You Have Any Query Or Specific Requirement? Ask to Our Industry[emailprotected]https://www.researchmoz.us/enquiry.php?type=E&repid=2276986

Hematopoietic Stem Cell Transplantation (HSCT) Market: Regional analysis includes:

The Study Objectives Of This Hematopoietic Stem Cell Transplantation (HSCT) Market Report Are:

Contact:

ResearchMozMr. Rohit Bhisey,Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email:[emailprotected]

Browse More Reports Visit @https://www.mytradeinsight.blogspot.com/

More:
Hematopoietic Stem Cell Transplantation (HSCT) Market Segments, Opportunity, Growth and Forecast by End-use Idustry 2020-2026 - Cole of Duty

To Read More: Hematopoietic Stem Cell Transplantation (HSCT) Market Segments, Opportunity, Growth and Forecast by End-use Idustry 2020-2026 – Cole of Duty
categoriaBone Marrow Stem Cells commentoComments Off on Hematopoietic Stem Cell Transplantation (HSCT) Market Segments, Opportunity, Growth and Forecast by End-use Idustry 2020-2026 – Cole of Duty | dataJune 17th, 2020
Read All

Coronavirus: inside the UAE stem cell centre working to treat Covid-19 – The National

By daniellenierenberg

When Dr Yendry Ventura began work to set up the Abu Dhabi Stem Cell Centre in late 2018, there was, he says, nothing else "related to stem cell therapy in the emirate.

Fast forward to today and the situation has changed dramatically. After opening in December last year, the centre has already received international press coverage over to its research into a treatment for Covid-19.

Their groundbreaking work has involved taking stem cells from a patients blood and returning them, via a nebuliser, as a fine mist to the lungs.

There they help regenerate lung cells and improve the body's immune response by preventing an overreaction to the infection that can damage healthy cells.

What characterises the method, says Dr Ventura, is that very little manipulation of the cells is needed for the treatment to be effective.

The future for the stem cells lies in regenerative medicine, in which you can treat almost all the degenerative conditions.

Dr Yendry Ventura

We separate a specific layer of cells from the blood, Dr Ventura told The National. Were the first one to use these cells with this route with this method.

We believe this way the cells can be aimed much better to the affected organs - the upper and lower respiratory tract.

In April, the centres efforts to develop a Covid-19 treatment resulted in the recovery of all 73 patients the treatment was initially trialled on. A quarter had been in intensive care.

The results appeared so promising that this month the centre secured intellectual property rights to the technique, allowing the treatment to be widely licensed, including to facilities abroad.

The ongoing work is a case of the centres specialists applying their expertise to best effect to help in a time of crisis, Dr Ventura said.

But the research is a departure from the facilitys usual purpose, which involves developing cutting-edge stem cell treatments for conditions such as cancer and heart disease.

Stem cells were first extracted from humans and grown in laboratories less than a quarter of a century ago.

The human body is mostly made of specialised cell types, such as heart muscle cells, kidney cells or nerve cells, all of which have a particular form related to their function.

Stem cells, however, have not yet undergone the process of developing into a specialised cell type, and are able to be manipulated to perform specific a function.

In adults, stem cells are found in tissues including fat and bone marrow, and these can be turned into multiple cell types.

One technique that the Abu Dhabi Stem Cell Centre plans to implement is haematopoietic stem cell transplantation, which involves stem cells being removed from an individual who is due to have cancer treatment.

The cells are then processed in a laboratory and injected into the patient after they have undergone chemotherapy or radiotherapy.

In this way, they can replace stem cells destroyed by the treatment, allowing a patient to tolerate a higher dose of therapy.

Dr Ventura says that similar treatments were applicable to most cancers of the blood as well as cancers that produce solid tumours.

There are many of these therapies still in research stage, but if you conquer this research, you can have a programme in which you can ... treat many kinds of cancers at the same time in one centre, he said.

The reality is that cell therapy is curing cancer We need to improve this therapy and make it available for many other people.

The future for the stem cells lies in regenerative medicine, in which you can treat almost all the degenerative conditions.

You can create in the future, if you have the right technologies, even artificial organs.

Set up with private sector funding in collaboration with the UAE authorities, the Abu Dhabi Stem Cell Centre works closely with experts at Sheikh Khalifa Medical City.

But the institution has stressed it is keen to forge further partnerships with both public and private sector medical institutions.

Currently, it operates seven days a week and has more than 100 staff, including nurses, technicians and doctors specialising in immunology, haematology, pathology, orthopaedics, urology and radiology.

In another initiative, the facility has recently begun running Minimal Residual Disease tests, which look at how many malignant cells remain in a patients blood or bone marrow.

These tests are useful for people with a variety of blood cancers, including lymphoma, leukaemia and myeloma. But they require fresh samples from the patient, so the lack of UAE testing facilities has, until now, required patients to travel abroad.

We try to implement the tests here in the Abu Dhabi Stem Cell Centre so the patient does not need to travel anymore, said Dr Ventura.

Updated: June 16, 2020 12:43 PM

Continued here:
Coronavirus: inside the UAE stem cell centre working to treat Covid-19 - The National

To Read More: Coronavirus: inside the UAE stem cell centre working to treat Covid-19 – The National
categoriaBone Marrow Stem Cells commentoComments Off on Coronavirus: inside the UAE stem cell centre working to treat Covid-19 – The National | dataJune 16th, 2020
Read All

Trial Omitting Total Body Irradiation Before HSCT Stopped Early – Medscape

By daniellenierenberg

Hematopoietic stem cell transplantation (HSCT) may offer the chance of a cure for patients with leukemia and other blood cancers, but the process of preparing the body to receive such a transplant can be brutal, involving whole body irradiation as well as chemotherapy conditioning. New results show that both steps are needed: a trial that omitted whole body irradiation in young patients with acute lymphoblastic leukemia (ALL) was stopped early because of significantly poorer outcomes.

The multicenter, global FORUM (For Omitting Radiation Under Majority Age) trial involved 75 centers in 17 countries between 2013 and 2018.

"Our study shows significantly better outcomes for total body irradiation compared to myeloablative chemo-conditioning arms, with no differences between the [two]chemo-conditioning groups," concluded Christina Peters, MD, professor of pediatrics in the Department of Stem Cell Transplantation at St Anna Children's Hospital in Vienna, Austria.

The findings in favor of total body irradiation were pronounced enough that the study was halted early by a safety committee, she added.

Peters presented the findings as part of the virtual European Hematology Association (EHA) 25th Annual Congress 2020.

Describing the results as "sobering," session co-moderator Shai Izraeli, MD, director of the Department of Hematology-Oncology at Schneider Children's Medical Center, in Petah Tikva, Israel, said an online comment from the virtual meeting audience reflected the reaction to these unwelcome results: "So we are still stuck with total body irradiation?"

Peters responded the good news is that the number of patients needing to undergo stem cell transplants is low, and with research advances, may hopefully drop even further.

"Only 10% of patients under the age of 18 nowadays undergo allogeneic HSCT, and perhaps in the future that will become even less if we are able to rescue some of the groups with other immunological measures such as CAR-T cells and antibodies," she said.

"I think it is very important to better identify those who really need total body irradiation in the future," she added.

Commenting for Medscape Medical News, Izraeli agreed.

"The prognosis of children after bone marrow transplantation is excellent the majority are cured from their leukemia," he said. "And we have to remember that those who undergo bone marrow transplant have the worst leukemias."

He pointed out that, in fact, contemporary chemotherapy alone is effective in the treatment of more than 90% of patients with ALL younger than aged 18.

For the 10% of patients who do not respond to chemotherapy alone and undergo allogeneic HSCT, about 50% to 80% of pediatric patients who have resistant leukemia are cured. However, the total body irradiation used to prepare the body to receive the transplant is linked to potentially serious consequences later in life, including sterility, lung problems, growth retardation, and secondary cancer.

To determine if the irradiation component could be safely replaced with a chemotherapy-based conditioning approach, Peters and colleagues conducted the FORUM trial.

In total 413 patients undergoing HSCT were enrolled and randomized to pretransplant conditioning with total body irradiation and etoposide (n = 202) or a chemotherapy-only approach with fludarabine/thiotepa/busulfan (flu/thio/bu; n = 99) or fludarabine/thiotepa/treosulfan (treo; n = 93).

Most patients (72%) had B-cell precursor ALL and 23% had T-cell ALL. Just over half (54%) were transplanted in first complete remission (CR1), 40% in CR2, and 4% in CR3.

The source of stem cells was bone marrow for most patients (82%); peripheral blood stem cell for 12%, and cord blood for 4%.

The aim of the study was to demonstrate noninferiority with the chemotherapy approach.

However, the significantly inferior outcome observed in the chemotherapy-only group led to randomization being halted in March 2019.

The 2-year overall survival in the intent-to-treat (ITT) analysis, with a mean observation time of 2.1 years, was 0.75 0.04 for chemo-conditioning versus 0.91 0.02 for total body irradiation/etoposide (ITT P < .001).

The ITT analysis showed relapses were significantly higher in the chemo-conditioning group (2-year cumulative incidence of relapse [CIR], 0.33) compared with the total body irradiation group (CIR, 0.12; P < .001).

The 2-year event-free survival (EFS) rate was also significantly higher in the total body irradiation group (0.86 vs 0.58; P < .001), and transplant-related mortality over 2 years was lower with total body irradiation (0.02 vs 0.09; P = .02).

A per-protocol analysis showed the 2-year overall survival to be the same in the two chemotherapy groups (both 0.77 0.05) compared with 0.91 0.02 in the total body irradiation group (P = .003).

"In this cohort [the 91% overall survival rate] may even be lower than contemporary intensive frontline therapy results that are achieved nowadays," Peters said.

In looking at subgroups, there were no significant differences according to age group or cancer phenotype, while MLL rearrangement was associated with higher relapse incidence.

Remission status was found to notably influence EFS, dropping from 0.91 in CR1 patients with total body irradiation to 0.76 in CR2 patients. However, total body irradiation remained significantly higher compared with the chemo-conditioning groups in CR1 (P = .004) and CR2 (P < .001).

Transplant-related mortality was not significantly different between the total body irradiation and chemo-conditioning groups in the CR1 or CR2 groups (P = .09 and P = .18, respectively), despite the significant difference when remission status was not included.

Overall, "we tried to identify subgroups in which total body irradiation might be eliminated, however in all analyses, total body irradiation was better than chemo-conditioning in all arms," Peters said.

Meanwhile, the findings underscore that even when patients cannot receive total body irradiation, the alternative chemo-conditioning therapy in fact shows favorable efficacy on its own, Izraeli said.

"The prognosis of the chemotherapy group is also quite remarkably good, although less than the total body irradiation arm. This means that if for some reason total body irradiation cannot be given, the chemotherapy is a very reasonable alternative."

Peters has reported relationships with Amgen, Novartis, Pfizer, Medac, Jazz, and Neovii. Izraeli has reported no relevant financial relationships.

EHA 2020 Congress. Presented June 12, 2020. Abstract S102.

For more from Medscape Oncology, join us on Twitter and Facebook.

Continue reading here:
Trial Omitting Total Body Irradiation Before HSCT Stopped Early - Medscape

To Read More: Trial Omitting Total Body Irradiation Before HSCT Stopped Early – Medscape
categoriaBone Marrow Stem Cells commentoComments Off on Trial Omitting Total Body Irradiation Before HSCT Stopped Early – Medscape | dataJune 16th, 2020
Read All

COVID-19 and cancer care – Pursuit

By daniellenierenberg

People with cancer may have compromised immunity due to their disease or its treatment. Early reports suggest cancer is a risk factor for severe COVID-19 disease as a result, many patients with cancer, and their families, are concerned about the risks and impacts of COVID-19.

Their concerns and distress are likely to be compounded by extensive media coverage of the pandemic, rapid changes in information about COVID-19 and continuing uncertainty about how to contain the disease.

On top of this, community transmission of COVID-19 has threatened the capacity of cancer services to provide routine investigations and care. In some cases, this has seen a prioritisation or modification of patients cancer therapies.

For example, chemotherapy may be postponed as this can compromise the immune system and make patients more vulnerable to developing COVID-19 disease.

Patients and families may, in turn, be frightened about not receiving proper treatment.

Read more

Another cause for concern is the change in the routine clinical management of cancer patients, partly because patients fear being infected. In Victoria, cancer hospitals have reported a 40 per cent decline in patient presentations for cancer management appointments since the stay-at-home guidelines in late March 2020.

This has raised concern among oncology health professionals about the health and wellbeing of vulnerable cancer patients whose health outcomes are likely to be negatively affected.

As patients are presenting less to hospital, it becomes crucial to develop new ways of identifying any distress in order to provide high-quality cancer management and supportive care.

The restrictions imposed by governments have been effective in limiting the spread of COVID-19, but social distancing, quarantine and visitor limitations have also reduced the opportunity for family support and connection important sources of strength and wellbeing.

These same government restrictions have also increased the use of telehealth to deliver care to cancer patients during COVID-19. Telehealth tools include simple patient health portal messages to relieve triage phone lines, e-consultation and telephone or video-based virtual visits.

Read more

The latest data from the Victorian COVID-19 Cancer Networks Telehealth Expert Group found that all of Victorias health services were now using telehealth for cancer care. And these tools may continue to expand, allowing greater access to supportive care beyond this crisis.

However, as useful as it is, this technology may pose issues of trust, isolation, disconnectedness and worries about abandonment as patients no longer benefit from the reassuring structure of the hospital oncology setting.

Telehealth may also not be possible for patients without a computer or internet access, which may create inequities in psychosocial care.

These issues should be considered if we upscale telehealth procedures for cancer patients and want to keep the best changes after the pandemic.

With respect to COVID-19, people with blood cancer are a particularly vulnerable group and require specialised attention and care. This is because blood cancers affect the production and functions of cells created in the bone marrow, which produces all the cells of our immune system.

Additionally, treatment for blood cancers compromise the immune system further, placing patients at very high risk of opportunistic infections, often for an extended period.

Read more

Even common respiratory viruses, like colds, can threaten survival. As a result, blood cancer specialists have recommended heightened surveillance and protective isolation for people with blood cancers.

A second major issue for blood cancer patients during the COVID-19 pandemic is the availability of donor stem cell products for patients undergoing haematopoietic stem cell transplantation.

Approximately 350 stem cell transplants are performed in Australia every year to treat blood cancers like leukaemia and multiple myeloma.

But finding a suitable stem cell donor is incredibly challenging, and about 80 per cent of donated stem cells come from overseas donors.

Unfortunately, COVID-19 has impacted donor availability due to border restrictions, flight changes and fear of becoming infected, creating very fearful scenarios for those waiting for potentially life-saving stem cell transplantation.

Victoria has already reported a case of a donor cancellation at short notice because the donor was worried about having been in contact with somebody with COVID-19.

The emotional consequences of the COVID-19 pandemic for people with blood cancers cannot be underestimated, nor can the consequences for the healthcare providers who care for them.

Read more

The COVID-19 pandemic has had a serious and disruptive effect.

In the short term, staff and resources at many hospitals have been reassigned to manage the rush of patients with COVID-19. Healthcare providers are faced with ethical dilemmas and required to make difficult treatment decisions without evidence-based guidelines.

Estimating the risk versus the benefit of administering potentially immunosuppressive treatment to patients with haematological cancers with a scarcity of knowledge about this novel disease, and balancing the individual and societal benefits with stretched resources, poses acute ethical dilemmas.

Making these challenging decisions can create fertile grounds for burnout and trauma.

More than ever, we need to develop ways to nurture healthcare providers.

Consideration of their unique experiences and needs during these exceptionally difficult times is important and we need to flexibly develop services to respond to those needs now and beyond this crisis.

But in developing such services, as well as recognising unmet needs, we have to acknowledge the problem-solving skills, resourcefulness and innovation that patients and healthcare providers have already undertaken as they have strived to adapt to managing cancer during COVID-19.

Banner: Getty Images

Read the rest here:
COVID-19 and cancer care - Pursuit

To Read More: COVID-19 and cancer care – Pursuit
categoriaBone Marrow Stem Cells commentoComments Off on COVID-19 and cancer care – Pursuit | dataJune 16th, 2020
Read All

Plinabulin Combo May Be Superior Therapy for Prevention of Chemotherapy-Induced Neutropenia – Targeted Oncology

By daniellenierenberg

Treatment with plinabulin in combination with pegfilgrastim (Neulasta) achieved the primary end point and several key secondary end points in the phase 3 PROTECTIVE (Study 106) clinical trial, which evaluated the combination compared with pegfilgrastim alone for superiority in chemotherapy-induced neutropenia prevention, according to the interim results announced by BeyondSpring, developer of the drug.

These results demonstrate significant enhancement to granulocyte colony-stimulating factors (G-CSFs) with the combination compared with pegfilgrastim alone for the prevention of grade 4 or severe neutropenia, supporting the potential for superiority with the combination compared with pegfilgrastim alone.

These interim results from the PROTECTIVE-2 Phase 3 study, which compares the Plinabulin-Neulasta combination to Neulasta alone, have the potential to be clinically meaningful for cancer patients receiving chemotherapy, stated Douglas W. Blayney, MD, professor of Medicine at Stanford Medical School and global principal investigator of Plinabulins chemotherapy-induced neutropenia studies. Since most infections, hospitalizations, and other complications of chemotherapy-induced neutropenia occur in the first week after chemotherapy, it is particularly gratifying to see the combinations clinical benefit demonstrated.

The primary end point was the rare of severe neutropenia prevention in cycle 1 (P <.01). The key secondary end points included duration of severe neutropenia in cycle 1 (P <.05) and duration of severe neutropenia in the first 8 days of cycle 1 (P <.05). The achievement of these end points demonstrates the agents ability to provide early protection against severe neutropenia induced by chemotherapy.

The interim analysis of the double-blind, active-controlled, global PROTECTIVE-2 study was pre-specified for the first 120 patients accrued. The study also has procedures in place for the prevention of potential bias after the planned interim analysis, and BeyondSpring opted to be informed by independent statisticians on whether the pre-specified P values were met rather than the exact P values.

The study was designed to assess both the safety and efficacy of plinabulin in patients with breast cancer treated with docetaxel, doxorubicin, and cyclophosphamide (TAC) in a 21-day cycle. Plinabulin was administered in a 40 mg dose on day 1 with a 6 mg dose of pegfilgrastim on day 2, while pegfilgrastim was administered at the same 6 mg dose on day 2 in the control arm. TAC is considered a high-risk chemotherapy regimen associated with neutropenia.

PROTECTIVE-2 is a superiority study for chemotherapy-induced neutropenia efficacy compared with pegfilgrastim alone and is currently enrolling patients. Grade 4 neutropenia rate for TAC and pegfilgrastim is observed in 83% to 93% of patients, which represents a severe unmet medical need.

The study drug and G-CSF have complementary mechanisms of action for preventing chemotherapy-induced neutropenia. Plinabulin is a first-in-class differentiated immune and stem cell modulator, which is currently in late-stage clinical development as a potential treatment for increasing overall survival in patients with cancer in addition to its ability to alleviate chemotherapy-induced neutropenia.

Plinabulin is also under evaluation in a phase 3 study as a direct anticancer drug as treatment of patients with nonsmall cell lung cancer and 2 phase 3 studies for the prevention of chemotherapy-induced neutropenia. The data for this agent in preventing chemotherapy-induced neutropenia highlights its ability to boost the number of hematopoietic stem or progenitor cells (HSPcs), as well as lineage-/cKIT+/Sca1+ cells in mice. Plinabulins effects on HSPcs may explain its ability to treat chemotherapy-induced neutropenia as well as its ability to reduce chemotherapy-induced thrombocytopenia and increase circulating CD34-positive cells.

To be included in the study, patients should be candidates for TAC in either the adjuvant or neoadjuvant setting, have early-stage breast cancer, and have received no prior chemotherapy. Patients must also have an ECOG performance status of 0 or 1 and a life expectancy of at least 3 months. Patients cannot be included in the study if they have a history of myelogenous leukemia, myelodysplastic syndrome, or sickle cell disease; use of CYP3A4, CYP2D6 or P-glycoprotein inhibitors and inducers within 14 days prior to receiving the study drug; or have received an investigational agent or tumor vaccine within 2 weeks, any concurrent anticancer therapies, or a bone marrow or stem cell transplantation.

These results could help to confirm the patient benefit of Plinabulins different mechanism of action from the G-CSF-based agents, such as Neulasta, Blayney stated. Plinabulin appears to have chemotherapy-induced neutropenia protection in Week 1, and G-CSFs have protection in Week 2 of chemotherapy cycles. The combination should logically provide significantly better protection than Neulasta alone as shown in the interim readout. We are well on our way to confirming that the combination offers protection throughout the chemotherapy cycle, which is an unmet medical need.

Reference

BeyondSpring Announces Positive Topline Interim Results from PROTECTIVE-2 (Study 106) Phase 3 Trial Evaluating Superiority of Plinabulin in Combination with Neulasta for Chemotherapy-Induced Neutropenia Prevention. NewsRelease. BeyondSpring. June 15, 2020. Accessed June 15, 2020. https://bit.ly/2YDJbiQ

More here:
Plinabulin Combo May Be Superior Therapy for Prevention of Chemotherapy-Induced Neutropenia - Targeted Oncology

To Read More: Plinabulin Combo May Be Superior Therapy for Prevention of Chemotherapy-Induced Neutropenia – Targeted Oncology
categoriaBone Marrow Stem Cells commentoComments Off on Plinabulin Combo May Be Superior Therapy for Prevention of Chemotherapy-Induced Neutropenia – Targeted Oncology | dataJune 16th, 2020
Read All

Children’s Hospital Los Angeles Ranked No. 1 Children’s Hospital in the Western U.S., No. 5 Nationally for Second Straight Year – Newswise

By daniellenierenberg

Newswise LOS ANGELES (June 16, 2020) Children's Hospital Los Angeles (CHLA) ranks again among the nations premier destinations for pediatric care, according to the U.S. News & World Report Best Children's Hospitals annual list released today.

CHLA not only retained its national No. 5 ranking in U.S. News Honor Roll of Best Childrens Hospitalswhich recognizes institutions with the most outstanding pediatric clinical careit continued its four-year streak of being the highest-scoring childrens hospital in the entire Western United States.

To make U.S. News & World Reports prestigious Best Childrens Hospitals Honor Roll, one must demonstrate the strongest achievements in clinical excellence, with a matchless team of expert, compassionate specialists committed to research and education as well as protocols that drive safety and quality and consistently lead to the best health outcomes for patients, says CHLA President and Chief Executive Officer Paul S. Viviano. "This honor affirms the work of every CHLA team member and our belief that when parents choose Childrens Hospital Los Angeles, they are choosing the best care for kids."

Every year, U.S. News scores nearly every major hospital and health system in the country and ranks them according to performance benchmarks, peer review, certifications, and other data provided by the hospital and third-party measurements of excellence. Children's hospitals are ranked separately from other facilities due to the specialized expertise, equipment and facilities required to care for infants, children and youth.

This year, U.S. News surveyed 118 pediatric medical centers, including hospitals that are freestanding or part of a larger institution. CHLA improved its ranking over last year in seven of the 10 pediatric specialty categories the survey considers, including a number two ranking for Neonatal Care. In all, the hospital earned top-10 recognition in seven of those categories:

CHLA has an organization-wide commitment to providing our patients the care they need no matter their circumstances, says CHLA Chief Medical Officer James Stein, M.D., MSc. "Our clinical teams often treat the most acute cases that are outside the scope or expertise of other childrens hospitals in California, and being named a Top-5 childrens hospital in the U.S. is a testament to the clinicians and staff who work every day to make sure each child receives the best care and experience possible.

Founded in 1901, Children's Hospital Los Angeles is a pediatric academic medical center built around its mission of creating hope and building healthier futures for children. Renowned for its world-class clinical care, leading-edge research and one of the largest and most successful pediatric training programs in the countryall while being the pediatric safety net hospital for the entire regionCHLA now sees more than 600,000 patient visits annually between its main hospital and five neighborhood care clinics.

CHLA physicians, nurses and clinical staff provide compassionate and lifesaving pediatric care for patients ranging from infants to young adults, hailing from all 50 states and more than 75 countries. Clinical care is led by physicians who are faculty members of the Keck School of Medicine of USC. Many of the hospital's achievements in care are made possible through a cohesive relationship between clinical experts at the bedside and the basic, translational, and clinical research conducted in The Saban Research Institute of CHLA.

In the past year, CHLA has had several notable achievements, including:

U.S. News and World Report works with research firm RTI International to develop its annual Best Children's Hospitals list, a collaboration between hospitals and the magazine to benchmark the performance of childrens hospitals for the benefit of parents and their children. The survey evaluates hundreds of data points, including patient survival and surgical complication rates; staffing, technology and special services; infection prevention and delivery of care; reputation among peer physicians nationwide (i.e. Where would the best pediatric specialists send their kids?); how involved parents are in their childrens care; and many other measurements of excellence.

U.S. News Media Group, the parent of U.S. News & World Report, announced the 2020-21 hospital rankings online at 12:01 a.m. EST on Tuesday, June 16. For additional information, please visit the Best Childrens Hospitals Honor Roll and specialty rankings page at usnews.com/childrenshospitals.

About Children's Hospital Los Angeles Founded in 1901,Children's Hospital Los Angelesis ranked the topchildrens hospital in California andfifth in the nation for clinical excellence with its selection to the prestigious U.S. News & World Report Honor Roll of childrens hospitals. Clinical care is led by physicians who are faculty members of the Keck School of Medicine of USC through an affiliation dating from 1932.The hospitalalso leads thelargest pediatric residency training program at a freestanding childrens hospital of its kind in the western United States.TheSaban Research Instituteof Childrens Hospital Los Angeles encompasses basic, translational and clinical research conducted at CHLA. The hospitals Global Health Program facilitates services for international patients from more than 75 countries. To learn more, follow us on Facebook, Instagram, LinkedIn and Twitter, and visit our blog for families (CHLA.org/blog) andour research blog (ResearCHLABlog.org).

View post:
Children's Hospital Los Angeles Ranked No. 1 Children's Hospital in the Western U.S., No. 5 Nationally for Second Straight Year - Newswise

To Read More: Children’s Hospital Los Angeles Ranked No. 1 Children’s Hospital in the Western U.S., No. 5 Nationally for Second Straight Year – Newswise
categoriaBone Marrow Stem Cells commentoComments Off on Children’s Hospital Los Angeles Ranked No. 1 Children’s Hospital in the Western U.S., No. 5 Nationally for Second Straight Year – Newswise | dataJune 16th, 2020
Read All

2025 Projection: Thalassemia Treatment Market Analysis by SWOT, Investment, Future Growth and Major Key Players 2020 to 2026 – Cole of Duty

By daniellenierenberg

COVID-19 impact will also be included and considered for forecast.

Global Thalassemia Treatment Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, Regional and Country Level.

Thalassemia Treatment Market Size Covers Global Industry Analysis, Size, Share, CAGR, Trends, Forecast And Business Opportunity.

>>Need a PDF of the global market report? Visit: https://industrystatsreport.com/Request/Sample?ResearchPostId=57&RequestType=Sample

Global Thalassemia Treatment Market 2018-2024Brandessence Market Research is working on a new report titleGlobal Thalassemia Treatment Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2018-2024?. Rise in number of altered Thalassemia genes, increase in awareness about the disease and high adoption of chelation therapy & blood transfusion for treatment by doctors as well as patients arelikely to enhance the growth of Global Thalassemia Treatment Market.

Scope of Global Thalassemia Treatment Market Reports

Thalassemia is aninherited blood disorder in which the body makes an abnormal form of hemoglobin.People having Thalassemia disease are unable to make sufficient hemoglobin which causes severe anemic conditions.Hemoglobin is found in red blood cells and transports oxygen to all parts of the body. When there is insufficient hemoglobin in the red blood cells, oxygen cannot get to all parts of the body. Organs demand oxygen and are unable to function properly.There are two primary types of Thalassemia disease such as Alpha Thalassemia disease and Beta Thalassemia disease.Alpha Thalassemia results in a formation of additional beta globins, which leads to the formation of beta-globin tetramers (4) called Hemoglobin H.

Beta Thalassemia causesadditionalformation of alpha globins, which develops alpha globin tetramers (a4) that store in the erythroblast (immature red blood cell).Thalassemia is caused by mutations in the DNA of cells that make hemoglobin.

Factors that increase risk of Thalassemia include Family history of thalassemia and certain ancestry.Possible complications of Thalassemia includeIron overload, Infections, Bone deformities, splenomegaly, slowed growth rate of child and Heart problems.

Thalassemia signs and symptoms include Fatigue, Weakness, Pale or yellowish skin, Facial bone deformities, slow growth, abdominal swelling, Dark urine, chest pain,cold hands and feet, poor feeding, greater susceptibility to infections. Diagnosis of Thalassemia includesa complete blood count (CBC), a reticulocyte count,Iron count, Genetic testing and prenatal testing. Treatment of Thalassemia depends on the type and severity of Thalassemia such as Blood transfusions, Bone marrow or stem cell transplant, Surgery and Gene therapy.

Global Thalassemia Treatment Market has been segmented on the basis ofType of Treatment, Diagnosis, End usersand Geography. On the basis of Type of TreatmentGlobal Thalassemia Treatment Market is classified into Blood Transfusion, Chelating Therapy, Bone Marrow Transplant, Stem Cell Transplant, Surgery, Gene Therapy and Others.On the basis of DiagnosisGlobal Thalassemia Treatment Market is classified into Perinatal Testing, Prenatal Testing, Pre-Implantation and Other.On the basis of the End user the Global Thalassemia Treatment Market is classified into Hospitals, Biotechnological Laboratories, Diagnostic Laboratories, Educational Research Institutes, Pharmaceutical Industries and others.

The regions covered in Global Thalassemia Treatment Market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, Global Melanoma Drug Market sub divided in to U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Key Players for Global Thalassemia Treatment Market Reports

Global Thalassemia Treatment Market reports cover prominent players like Bluebird bio Inc., Acceleron Pharma Inc., Novartis AG, Celgene Corporation, Shire plc, Bellicum Pharmaceuticals, GlaxoSmithKline Plc, Celgene,Lonza group, Alnylam Pharmaceuticals Inc., Calimmune Inc., CRISPR Therapeutics, Editas Medicine Inc., Errant Gene Therapeutics LLC, Gamida Cell Ltd, Gilead Sciences Inc., Incyte Corp, Ionis Pharmaceuticals Inc., IRBM Science Park SpA, Johnson & Johnson, Kiadis Pharma NV, La Jolla Pharmaceutical Company, Merck & Co Inc., PharmaEssentia Corp, Protagonist Therapeutics Inc., Sangamo Therapeutics Inc., Zydus Cadila Healthcare Ltd, Genorama Ltd, HiMedia Laboratories, DiagCor Bioscience Inc. Ltd and Tosoh Bioscience Inc.

Global Thalassemia Treatment Market Dynamics

Increase in awareness about the disease and technological expansions are likely to raise the adoption of gene therapies. Also Rising Prevalence of Thalassemia, Increase in Pharmaceutical R&D Spending, Increasing Spending on Stem Cell Research, Rising Healthcare Expenditure and Rising Asian Population will boost theGlobal Thalassemia Treatment Market. Treatment of Thalassemia is mostly restricted to regular blood transfusions and iron chelation therapy.Moreover, High operation cost of sophisticated clinical and preclinical imaging systems, High cost of maintenance andless life span of accessoriesalso restraining theGlobal Thalassemia Treatment Market.Yearlyspending for treatment of Thalassemia ranged from $ 108 to 432, depending on type of treatment with average cost per blood transfusion was $ 5.22.2. Average 18.5%14.3 of the total annual income was spent on the treatment for Thalassemia. Drugs prescribed for Thalassemia mostly cures symptoms and side effects such as anemia, iron overload, slow growth of children and vitamin deficiency.Occurrence of Thalassemia is reported to increase steadily over the years across different regions. This can be due to population migration, intermarriages, genetic as well as environmental factors prompting the condition and its implications.Systematic Drugs under Pipeline, Rising Scope for Gene Therapy and increasing awareness towards Thalassemia are some opportunities in the forecast period for theGlobal Thalassemia Treatment Market.

Global Thalassemia Treatment MarketRegional Analysis

North America have largest share ofGlobal Thalassemia Treatment Market. It is mainly driven by quickly increasing immigrant population from tropical regions, rising number of population with Thalassemia carrier gene and rise in birth rates due to variation of genes among the population in the U.S.There are some prenatal tests available on the market to determine the possibility of alpha thalassemia including both invasive and non-invasive technique.

The alpha thalassemia testing market has aemergent trend in the countries with traditional groups like Mediterranean countries, African countries and few countries in Asia Pacific. Furthermore, in Asia Pacific region the growth in similar community marriage practices and high fertility ratewith alpha thalassemia patients have been detected. This is expected to raiseacceptance of blood transfusion and chelation therapy treatments during the forecast period.A latestimprovement in the testing of alpha Thalassemia may determine the risk of the disease by in vitro examination of the embryo. While there are various such tests available in theGlobal Thalassemia Treatment Market but lack of awareness leads to the neglect and delayed diagnosis of the diseased state.

Most frequently prone area for alpha thalassemia is Mediterranean countries, African countries, and Southeast Asian countries. Thalassemia trait practically affects 6% to 35% of the population in these ethnic groups. Middle East & Africa is likely to be the fastest risingGlobal Thalassemia Treatment Market during the forecast period.

Key Benefits for Global Thalassemia Treatment Market Reports

Global Thalassemia Treatment Market report covers in depth historical and forecast analysis.Global Thalassemia Treatment Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Global market sale (K Units), Global market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level.Global Thalassemia Treatment Market report helps to identify opportunities in market place.Global Thalassemia Treatment Market report covers extensive analysis of emerging trends and competitive landscape.Global Thalassemia Treatment Market Segmentation

Global Thalassemia Treatment Market: By Type of Treatment Analysis

Blood TransfusionChelating TherapyBone Marrow TransplantStem Cell TransplantSurgeryGene TherapyOtherGlobal Thalassemia Treatment Market: By Diagnosis Analysis

Perinatal TestingPrenatal TestingPre-ImplantationOtherGlobal Thalassemia Treatment Market: By End user Analysis

HospitalsBiotechnological LaboratoriesDiagnostic LaboratoriesEducational Research InstitutesPharmaceutical IndustriesOtherGlobal Thalassemia Treatment Market: By Regional & Country Analysis

North AmericaU.S.MexicoCanadaEuropeUKFranceGermanyItalyAsia PacificChinaJapanIndiaSoutheast AsiaLatin AmericaBrazilThe Middle East and AfricaGCCAfricaRest of Middle East and AfricaNeed a PDF of the global market report? Visit: https://industrystatsreport.com/Request/Sample?ResearchPostId=57&RequestType=Methodology

Table of Content:

Market Overview: The report begins with this section where product overview and highlights of product and application segments of the Global Thalassemia Treatment Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition by Company: Here, the competition in the Worldwide Global Thalassemia Treatment Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data: As the name suggests, this section gives the sales data of key players of the Global Thalassemia Treatment Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the Global Thalassemia Treatment Market.

Market Status and Outlook by Region: In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the Global Thalassemia Treatment Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User: This section of the research study shows how different end-user/application segments contribute to the Global Thalassemia Treatment Market.

Market Forecast: Here, the report offers a complete forecast of the Global Thalassemia Treatment Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion: This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

See the rest here:
2025 Projection: Thalassemia Treatment Market Analysis by SWOT, Investment, Future Growth and Major Key Players 2020 to 2026 - Cole of Duty

To Read More: 2025 Projection: Thalassemia Treatment Market Analysis by SWOT, Investment, Future Growth and Major Key Players 2020 to 2026 – Cole of Duty
categoriaBone Marrow Stem Cells commentoComments Off on 2025 Projection: Thalassemia Treatment Market Analysis by SWOT, Investment, Future Growth and Major Key Players 2020 to 2026 – Cole of Duty | dataJune 16th, 2020
Read All

Page 10«..9101112..2030..»